Cellular Agriculture Ingredients Market Size & Share 2026-2035

Cellular Agriculture Ingredients Market Size

The cellular agriculture ingredients market was valued at USD 1.1 billion in 2025 and is projected to reach USD 8.78 billion by 2035, expanding at a CAGR of 23.1% over 2026–2035. According to the latest report published by Global Market Insights Inc., 2026 revenue reaches USD 1.38 billion.

The addressable opportunity centers on commercially usable functional ingredients rather than finished alternative-protein products alone. Fermentation capacity, regulatory clearance, and formulation adoption now determine whether technical platforms convert into recurring B2B revenue.

The market covers bio-derived proteins, fats and lipids, enzymes, flavors and aromatics, cell culture media components, and scaffolds and matrices produced through biomass fermentation, precision fermentation, or cultivated/cultured technologies. It includes B2B suppliers and vertically integrated producers where fermentation-derived ingredients support their finished portfolios. Conventional dairy, eggs, plant-based ingredients made without fermentation or cell culture, standard yeast extracts, and general industrial enzymes fall outside scope.

The market’s forecast revenue pool totals USD 43.8 billion across 2026–2035. Proteins remain the principal value pool, while media components, fats, and scaffolds add strategically important demand as cultivated programs progress. The more consequential transition is from pilot-led ingredient launches to repeatable procurement by food, nutrition, cosmetics, and bioprocessing customers.

The revenue forecast and volume forecast do not move at the same speed. Scaling biomass fermentation raises output through established production systems, while precision fermentation adds value through differentiated functional molecules and higher realized prices. That distinction makes revenue leadership less dependent on total tonnage than on product mix. It also explains why regulatory milestones carry greater value for specialty proteins than for bulk ingredients: a cleared ingredient can enter a customer qualification process before it reaches commodity scale. GFI’s industry coverage documents the continuing importance of commercial capacity, financing, and downstream demand in turning technical progress into market revenue. ^{[1]Good Food Institute, "State of the Industry: Fermentation," gfi.org}

The market combines established mycoprotein production with newer precision-fermented protein platforms and earlier-stage cultivated-material programs. Regulatory outcomes are a commercial filter, not merely a compliance event: GRAS notifications give suppliers a usable route into US customer qualification, while Regulation (EU) 2015/2283 remains the EU market-access gateway. ^{[2]U.S. Food and Drug Administration, "GRAS Notice Inventory," fda.gov}

Key Drivers

Precision fermentation maturation changes the addressable market because it supports precise functional targets rather than generic protein substitution. Commercial yields above 100 g/L and an approximately 85% production-cost reduction since 2019 have improved the economics of specialty dairy, egg, and structural proteins. That technical progress matters most in applications where functionality and supply security justify a premium. FDA records show sequential clearances for Geltor’s GRN 1171, Impossible Foods’ GRN 1202, TurtleTree’s GRN 1219, and Onego Bio’s GRN 1249.

Regulatory clearance translates laboratory capability into customer-facing commercial options. The US GRAS pathway has created a more legible procurement environment for food manufacturers, while the EU Novel Food framework establishes a separate but increasingly relevant route for European deployment. ^{[3]European Commission, "Regulation (EU) 2015/2283 on Novel Foods," europa.eu} The result is a widening set of ingredients that can enter formulation trials without the uncertainty associated with unreviewed novel-food inputs.

Sustainability procurement adds a second demand mechanism beyond direct ingredient economics. Food and beverage manufacturers with emissions objectives can use fermentation-derived proteins and mycoprotein to alter the footprint of existing formulations. Hybrid formulations are commercially important because they let buyers use high-functionality ingredients at partial substitution rates before full commodity parity emerges.

Key Restraints

Commercial capacity remains the sector’s binding constraint. Dedicated fermentation facilities require sterile processing, specialist bioreactors, qualification work, and extended commissioning periods. Investments estimated at USD 200–500 million per facility make the move from pilot output to dependable, high-volume supply difficult. This constraint favors companies using manufacturing partnerships, licensing, or existing fermentation infrastructure rather than relying solely on greenfield assets.

Consumer acceptance is less acute for a B2B ingredient sale than for a finished branded product, yet it still affects customer willingness to scale. Precision fermentation must be explained clearly where labels and genetically engineered production systems prompt scrutiny. Familiar fermentation categories such as bread, cheese, and beer offer a reference point, but they do not eliminate the need for evidence-led claims, clear labeling, and consistent sensory performance.

Cellular Agriculture Ingredients Market Segment Analysis

By Ingredient Type

Proteins led the cellular agriculture ingredients market with 69% share and USD 759 million in 2025. The category spans Quorn and Planetary Group mycoprotein, Nature’s Fynd Fy™, Perfect Day ProFerm™, TurtleTree LF+, The EVERY Company OvoPro™ and OvoBoost™, Onego Bio Bioalbumen®, and Geltor PrimaColl® and HumaColl™21. Its leadership reflects both the long commercial history of mycoprotein and the growing number of premium precision-fermented protein applications. By 2035, protein revenue will exceed USD 6,000 million, although share will moderate as media and scaffold demand expands.

Cell culture media components ranked second at 10% and USD 110 million in 2025. These inputs include growth factors, recombinant serum albumins, amino-acid blends, and specialized media for cultivated-food systems. IntegriCulture’s CulNet Consortium, established in September 2024, targets co-culture-based serum-free media development and points to a path for reducing growth-factor costs. ^{[4]APAC Society for Cellular Agriculture and Cellular Agriculture Australia, "Partnership Announcement," cellularagricultureaustralia.org} Fats and lipids held 8% and USD 88 million, followed by enzymes at 6% and USD 66 million, flavors and aromatics at 4% and USD 44 million, and scaffolds and matrices at 3% and USD 33 million. Scaffolds remain research- and pilot-led today, but demand should accelerate in the 2028–2032 period as cultivated programs require food-grade structural materials.

By Technology

Biomass fermentation generated 52% of 2025 revenue, equivalent to USD 572 million. Quorn’s continuous fermentation of *Fusarium venenatum*, Nature’s Fynd Fy™ platform, and Planetary Group’s Libre® and BioBlocks™ show why this remains the sector’s most mature production route. Quorn’s established manufacturing base gives the technology a production and market-familiarity advantage that new platforms cannot replicate quickly. Monde Nissin reported a 9% revenue decline for Quorn in FY2024, but Marlow Foods remained EBITDA-positive in H1 2025, indicating that B2B manufacturing capability remained active. ^{[5]Monde Nissin Corporation, "Marlow Foods IFRS Accounts 2025," mondenissin.com}

Precision fermentation held 40% and USD 440 million in 2025. It produces targeted molecules through microbial hosts, enabling Onego Bio’s Bioalbumen®, Perfect Day’s ProFerm™, Geltor’s collagen portfolio, and The EVERY Company egg proteins. Regulatory clearances and product-specific functionality position this technology to become the largest revenue contributor around 2029–2030. Cultivated/cultured products held the remaining 8% and USD 88 million. GOOD Meat illustrates the strategic importance of this segment, but current commercial scale remains limited and media inputs are its most viable near-term ingredient opportunity.

By Application

Food and beverage dominated with 77% of 2025 revenue, or USD 847 million. Quorn mycoprotein, Perfect Day protein in Breyers formulations, and EVERY egg proteins in bakery and foodservice demonstrate the application’s breadth. Hybrid formulation is central because it allows manufacturers to deploy fermentation-derived functionality without redesigning every product around a single novel input. Food and beverage revenue will exceed USD 6,700 million by 2035, preserving its dominant position.

Pet food accounted for 7% and USD 77 million, while nutraceuticals and dietary supplements represented 6% and USD 66 million. TurtleTree LF+ and Geltor HumaColl™21 fit the latter category because purity and functional positioning influence purchase decisions. Cosmetics and personal care contributed 5% and USD 55 million, with Geltor PrimaColl® and Elastapure® serving premium structural-protein use cases. Bioprocessing and cell culture inputs also represented 5%, or USD 55 million, and will grow fastest as animal-free media components become part of validated production systems.

Cellular Agriculture Ingredients Market Regional Analysis

North America led the market with 39% share and USD 429 million in 2025. The United States concentrates Geltor, The EVERY Company, Perfect Day, Onego Bio, Nature’s Fynd, and New Culture, alongside an FDA GRAS system that has cleared several precision-fermented ingredients. Impossible Foods’ GRN 1202 closed on March 7, 2025, and Onego Bio’s GRN 1249 followed on September 16, 2025. Canada contributes through its novel-food framework and broader protein-diversification activity. North America will retain the largest revenue base, although its share will moderate as Asian capacity scales.

Asia Pacific held 26% and USD 286 million in 2025, making it the fastest-growing region. China’s food-manufacturing base, India’s fermentation-cost position, and innovation activity in Japan, South Korea, and Australia support the expansion. Perfect Day’s India joint venture becomes operational in H2 2026, strengthening the case for lower-cost regional production. The July 2025 partnership between the APAC Society for Cellular Agriculture and Cellular Agriculture Australia also extends regulatory advocacy capacity across the region. The regional constraint is uneven novel-food regulation, which makes market access less consistent than its manufacturing potential.

Europe represented 24% and USD 264 million in 2025. The UK remains central through Marlow Foods production and Better Dairy’s development work, while Switzerland hosts Planetary Group’s licensing and mycoprotein platform. Planetary Group launched Libre® at ALDI Suisse in July 2025 after receiving a CHF 3 million Royal Cosun investment in January 2025. ^{[6]Planetary Group, "Libre and BioBlocks Platform Updates," planetarygroup.ch} Regulation (EU) 2015/2283 determines EU access, creating a high evidentiary threshold but also a clearer route once approvals are secured.

Latin America accounted for 6% and USD 66 million. Brazil, Mexico, and Argentina offer food-manufacturing demand, but current adoption is import-led and conventional-protein economics remain a constraint. MEA represented 5% and USD 55 million, with the UAE, Saudi Arabia, and South Africa providing the most relevant demand centers. Food-security initiatives support long-term interest, although local regulatory frameworks and domestic production remain early-stage.

Cellular Agriculture Ingredients Market Share & Competitive Landscape

The market was moderately fragmented in 2025. Quorn led with 10.0% share, followed by Impossible Foods at 6.5%, Geltor at 5.0%, Nature’s Fynd at 2.7%, The EVERY Company at 1.8%, and TurtleTree at 0.7%. These six players held 26.7% collectively, while other named players held 5.0% and untracked participants accounted for 68.3%. Shares reflect 2025 cellular agriculture ingredient revenue and include the defined vertically integrated activity of Impossible Foods; they do not treat private-company sales as independently reported figures.

Competitive advantage comes from three assets: a differentiated ingredient platform, regulatory clearance, and a credible path to scale. Geltor’s PrimaColl®, HumaColl™21, and Elastapure® target premium structural-protein categories. The EVERY Company’s USD 55 million Series D financing in October 2025 supports scale-up of OvoPro™ and OvoBoost™. ^{[7]The EVERY Company press release, "The EVERY Company Raises USD 55 Million Series D," businesswire.com} Onego Bio combines Bioalbumen® with GRN 1249 clearance, while TurtleTree uses LF+ to address constrained lactoferrin supply.

Major players operating in the cellular agriculture ingredients market include:

• Established biomass-fermentation and integrated producers: Quorn, Nature’s Fynd, Impossible Foods, and Planetary Group.

• Precision-fermentation B2B specialists: The EVERY Company, Geltor, Perfect Day, Onego Bio, TurtleTree, New Culture, and Better Dairy.

• Boundary and cultivated-technology participants: Win-Win and GOOD Meat.

Nature’s Fynd retains FDA and Health Canada clearance for Fy™, but its April 2025 workforce reduction and reported revenue-to-funding gap introduce execution risk. Planetary Group combines Libre® supply with BioBlocks™ licensing, reducing the capital burden of geographic expansion. New Culture uses mozzarella as a commercialization vehicle for its casein platform. Better Dairy is pre-commercial, with osteopontin and casein milestones shaping its relevance after the base year. Win-Win produces a cocoa-free chocolate compound through traditional plant-substrate fermentation and remains at the boundary of the technical market definition. GOOD Meat is a cultivated-meat pioneer and R&D enabler rather than a conventional ingredient supplier; its Singapore scale remains minimal following the March 2025 ABEC settlement.

Nature’s Fynd retains FDA and Health Canada clearance for Fy™, but its April 2025 workforce reduction and reported revenue-to-funding gap introduce execution risk. Planetary Group combines Libre® supply with BioBlocks™ licensing, reducing the capital burden of geographic expansion. New Culture uses mozzarella as a commercialization vehicle for its casein platform. Better Dairy is pre-commercial, with osteopontin and casein milestones shaping its relevance after the base year. Win-Win produces a cocoa-free chocolate compound through traditional plant-substrate fermentation and remains at the boundary of the technical market definition. GOOD Meat is a cultivated-meat pioneer and R&D enabler rather than a conventional ingredient supplier; its Singapore scale remains minimal following the March 2025 ABEC settlement.

Recent Industry Developments

• Jun 2026: The Protein Brewery received EU Novel Food approval for Fermotein under Regulation (EU) 2015/2283. The approval expands the commercial reference base for fermentation-derived protein ingredients in the EU.

• Feb 2026: Amai Proteins received FDA GRAS GRN 1269 clearance. The decision expands the cleared precision-fermentation ingredient set in the US.